Cytek Biosciences Inc (CTKB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -6,807 | 2,484 | -1,234 | -2,860 | -2,158 |
| Depreciation Amortization | 1,801 | 5,659 | 3,795 | 3,024 | 1,470 |
| Accounts receivable | 6,055 | -19,744 | -11,780 | -7,964 | -1,038 |
| Accounts payable and accrued liabilities | 305 | 1,862 | 2,770 | 3,677 | 2,782 |
| Other Working Capital | 3,693 | -39,928 | -35,188 | -20,189 | -5,201 |
| Other Operating Activity | -2,189 | 37,436 | 23,213 | 13,392 | 2,665 |
| Operating Cash Flow | $2,858 | $-12,231 | $-18,424 | $-10,920 | $-1,480 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -123,239 | -44,454 | 0 | 0 | N/A |
| PPE Investments | -505 | -9,748 | -3,218 | -2,108 | -780 |
| Net Acquisitions | -44,895 | N/A | N/A | N/A | N/A |
| Purchase Of Investment | -235 | -1,587 | -1,587 | -1,587 | N/A |
| Purchase Sale Intangibles | N/A | -120 | -40 | N/A | N/A |
| Other Investing Activity | 0 | -120 | -40 | 0 | 0 |
| Investing Cash Flow | $-168,874 | $-55,909 | $-4,845 | $-3,695 | $-780 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | 2,983 | N/A | N/A | N/A |
| Debt Repayment | -146 | -50 | N/A | N/A | 0 |
| Common Stock Issued | 203 | 1,204 | 1,036 | 810 | 364 |
| Common Stock Repurchased | N/A | 1,585 | 765 | 765 | N/A |
| Other Financing Activity | -57 | -209 | -138 | -67 | 0 |
| Financing Cash Flow | $0 | $5,513 | $1,663 | $1,508 | $364 |
| Exchange Rate Effect | -1,090 | -2,491 | -1,489 | -1,617 | -216 |
| Beginning Cash Position | 299,500 | 364,618 | 364,618 | 364,618 | 364,618 |
| End Cash Position | 132,394 | 299,500 | 341,523 | 349,894 | 362,506 |
| Net Cash Flow | $-167,106 | $-65,118 | $-23,095 | $-14,724 | $-2,112 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,858 | -12,231 | -18,424 | -10,920 | -1,480 |
| Capital Expenditure | -505 | -9,748 | -3,218 | -2,108 | -780 |
| Free Cash Flow | 2,353 | -21,979 | -21,642 | -13,028 | -2,260 |